Kimberly-Clark Bets Over $40B on Kenvue Amid Tylenol Controversy -- Market Talk

Dow Jones

2025/11/03

0728 ET - Kimberly-Clark's more than $40 billion deal to buy Kenvue comes as the drugmaker has recently made headlines, after the Trump Administration linked Tylenol use during pregnancy to autism. President Trump and Health Secretary Robert F. Kennedy Jr. put out an official warning in September which stated that acetaminophen is a potential cause of autism, citing existing studies. Kenvue has repeatedly denied such claims, stating it hasn't found any casual association between acetaminophen use in pregnancy and neurodevelopmental disorders. Still, a citizen petition in September sought to change consumer labels on the popular pain reliever, and Texas last week sued Kenvue, alleging it hid autism risks of the pain reliever. Kenvue shares jump 20%, while Kimberly-Clark shares sink 15%. (connor.hart@wsj.com)

(END) Dow Jones Newswires

November 03, 2025 07:28 ET (12:28 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2580229076"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2580229076\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2580229076?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-03 20:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580229076","market":"sg","top_or_hot":-1,"title":"Kimberly-Clark Bets Over $40B on Kenvue Amid Tylenol Controversy -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0728 ET - Kimberly-Clark's more than $40 billion deal to buy Kenvue comes as the drugmaker has recently made headlines, after the Trump Administration linked Tylenol use during pregnancy to autism. President Trump and Health Secretary Robert F. Kennedy Jr. put out an official warning in September which stated that acetaminophen is a potential cause of autism, citing existing studies. Kenvue has repeatedly denied such claims, stating it hasn't found any casual association between acetaminophen use in pregnancy and neurodevelopmental disorders. Still, a citizen petition in September sought to change consumer labels on the popular pain reliever, and Texas last week sued Kenvue, alleging it hid autism risks of the pain reliever. Kenvue shares jump 20%, while Kimberly-Clark shares sink 15%. (connor.hart@wsj.com) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 03, 2025 07:28 ET (12:28 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kimberly-Clark Bets Over $40B on Kenvue Amid Tylenol Controversy -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKimberly-Clark Bets Over $40B on Kenvue Amid Tylenol Controversy -- Market Talk\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-11-03 20:28</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0728 ET - Kimberly-Clark's more than $40 billion deal to buy Kenvue comes as the drugmaker has recently made headlines, after the Trump Administration linked Tylenol use during pregnancy to autism. President Trump and Health Secretary Robert F. Kennedy Jr. put out an official warning in September which stated that acetaminophen is a potential cause of autism, citing existing studies. Kenvue has repeatedly denied such claims, stating it hasn't found any casual association between acetaminophen use in pregnancy and neurodevelopmental disorders. Still, a citizen petition in September sought to change consumer labels on the popular pain reliever, and Texas last week sued Kenvue, alleging it hid autism risks of the pain reliever. Kenvue shares jump 20%, while Kimberly-Clark shares sink 15%. (connor.hart@wsj.com) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 03, 2025 07:28 ET (12:28 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1267930573.SGD","symbol_name":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2580229076","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580229076","pubTimestamp":1762172880,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0728 ET - Kimberly-Clark's more than $40 billion deal to buy Kenvue comes as the drugmaker has recently made headlines, after the Trump Administration linked Tylenol use during pregnancy to autism. President Trump and Health Secretary Robert F. Kennedy Jr. put out an official warning in September which stated that acetaminophen is a potential cause of autism, citing existing studies. Kenvue has repeatedly denied such claims, stating it hasn't found any casual association between acetaminophen use in pregnancy and neurodevelopmental disorders. Still, a citizen petition in September sought to change consumer labels on the popular pain reliever, and Texas last week sued Kenvue, alleging it hid autism risks of the pain reliever. Kenvue shares jump 20%, while Kimberly-Clark shares sink 15%. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","KMB":"金佰利","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","BK4018":"居家用品","BK4567":"ESG概念","BK4585":"ETF&股票定投概念","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","LU2463526074.USD":"NORDEA 1 - GLOBAL CLIMATE ENGAGEMENT \"BP\" (USD) ACC","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","KVUE":"Kenvue Inc","BK4504":"桥水持仓","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","BK4183":"个人用品","BK4588":"碎股","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC"},"translate_title":"在泰诺争议中，金佰利(Kimberly-Clark)在Kenvue上押注超过40B美元——市场讨论","themeId":"d7f4f57ff2cf212a4a46fa1f7ed8723f","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KVUE":0.9,"KMB":1.5},"content_text":"0728 ET - Kimberly-Clark's more than $40 billion deal to buy Kenvue comes as the drugmaker has recently made headlines, after the Trump Administration linked Tylenol use during pregnancy to autism. President Trump and Health Secretary Robert F. Kennedy Jr. put out an official warning in September which stated that acetaminophen is a potential cause of autism, citing existing studies. Kenvue has repeatedly denied such claims, stating it hasn't found any casual association between acetaminophen use in pregnancy and neurodevelopmental disorders. Still, a citizen petition in September sought to change consumer labels on the popular pain reliever, and Texas last week sued Kenvue, alleging it hid autism risks of the pain reliever. Kenvue shares jump 20%, while Kimberly-Clark shares sink 15%. (connor.hart@wsj.com) \n\n\n  (END) Dow Jones Newswires\n\n\n  November 03, 2025 07:28 ET (12:28 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}